{'fraction_non_alphanumeric': 0.028513238289205704, 'fraction_numerical': 0.0, 'mean_word_length': 5.929577464788732, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate

A paradoxical plasma HDL‐Cholesterol (HDL‐C) reducing effect following combined fibrate and thiazolidinediones (TZDs) therapy was recently reported in occasional cases. As HDL‐C level is inversely related to cardiovascular disease (CVD) risk, we have studied the incidence of reduced HDL‐C level following mono‐ and combined therapy with these drugs in a large diabetic population.